Cargando…
Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma
BACKGROUND: The introduction of rituximab into the treatment of patients with non-Hodgkin’s lymphomas has improved the overall response rate, as well as the response duration and the overall survival of patients with B-cell lymphomas. But only a few studies have addressed the question whether the be...
Autores principales: | Horvat, Mateja, Novakovic, Barbara Jezersek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Versita, Warsaw
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423703/ https://www.ncbi.nlm.nih.gov/pubmed/22933921 http://dx.doi.org/10.2478/v10019-010-0044-6 |
Ejemplares similares
-
The predictive significance of CD20 expression in B-cell lymphomas
por: Prevodnik, Veronika Kloboves, et al.
Publicado: (2011) -
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
por: Horvat, Matej, et al.
Publicado: (2018) -
Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome
por: Rozman, Samo, et al.
Publicado: (2017) -
Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
por: Jezeršek Novaković, Barbara, et al.
Publicado: (2021) -
Treatment outcomes and survival in patients with primary central nervous system lymphomas treated between 1995 and 2010 – a single centre report
por: Jezersek Novakovic, Barbara
Publicado: (2012)